Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC) announced two notable achievements at World ADC San Diego 2026, held October 12–15: winning the conference's Best Poster Award for its Accum®-ADC research and leading a main-stage discussion alongside globally recognised antibody-drug conjugate experts. The recognition places the Montreal-based biotechnology company's proprietary drug-delivery technology in front of a key international scientific audience. Investors may be watching whether this profile boost accelerates the company's stated goal of securing pharmaceutical partnerships and licensing agreements.

Key Points

  • Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC) is a Montreal-based precision oncology biotechnology company.
  • The company won the Best Poster Award 2026 at World ADC San Diego for its presentation on the Accum® intracellular trafficking platform.
  • Defence also moderated a main-stage session on October 14, 2026, featuring senior scientists from Genentech and Bionavigen Oncology.
  • The company states the conference strengthened existing relationships and established new contacts to support Accum®-ADC partnership development.

Accum® Platform Earns Best Poster Honour at Leading ADC Conference

Defence Therapeutics received the Best Poster Award 2026 for a presentation entitled "Accum: A Plug-In Intracellular Trafficking Platform for Next-Generation ADCs," delivered by Dr. Guillaume Lefrançois, Senior Scientist at the company. The award recognises the firm's scientific work in intracellular trafficking and drug delivery, an area the company describes as increasingly central to ADC development. The release states that Dr. Lefrançois noted the honour reflects growing interest among drug developers in how intracellular delivery can contribute to the next generation of ADC therapeutics.

Defence Moderates Main-Stage Discussion on the Future of ADC Intracellular Delivery

Beyond its award-winning poster, Defence led a main-stage session on October 14, 2026, entitled "Beyond Antibody, Linker & Payload – Is Intracellular Delivery the Next Frontier for ADCs?" The session was moderated by Dr. Amie Phinney, President and CEO of Defence Therapeutics, and featured Gail Lewis, PhD, Distinguished Scientist at Genentech; Rakesh Dixit, PhD, CEO of Bionavigen Oncology; and board member John Lambert, PhD, who contributed via pre-recorded presentation. The discussion explored emerging technologies shaping next-generation ADC therapeutics.

Conference Engagements Support Defence's Accum®-ADC Partnership Strategy

The announcement states that Defence used the conference to strengthen existing relationships and establish new contacts with pharmaceutical companies, biotechnology innovators, and academic researchers. The company describes these engagements as supporting its strategy to advance Accum®-ADC enhancement programs through scientific collaborations and pharmaceutical partnerships, with the goal of creating future licensing and commercial opportunities. Dr. Phinney is quoted in the release stating that the company's focus is to translate scientific recognition and industry engagement into meaningful partnerships to create long-term shareholder value.